Related Experiment Video
Updated: Jun 26, 2025
Enhancing Tumor Content through Tumor Macrodissection
Published on: February 12, 2022
The association of the hepatitis B virus infection and diffuse large B-cell lymphoma
Guodong Yu1, Jijing Han1, Jianmei Xu1
1From the Department of Hepatobiliary Surgery (Yu), from the Department of Pediatrics (Han), and from the Department of Hematology (Xu), Affiliated Hospital of Hebei University, Baoding, China.
Insights
Hepatitis B surface antigen positive (HBsAg[+]) status is linked to worse survival in diffuse large B-cell lymphoma (DLBCL) patients. This finding highlights the need for focused clinical attention on HBsAg[+] DLBCL cases.
Area of Science:
- Oncology
- Hepatology
- Clinical Medicine
Background:
- Diffuse large B-cell lymphoma (DLBCL) is a common non-Hodgkin lymphoma.
- Hepatitis B virus (HBV) infection is a global health concern.
- The impact of HBV infection on DLBCL prognosis requires further investigation.
Purpose of the Study:
- To characterize patients with DLBCL.
- To determine if hepatitis B surface antigen positive (HBsAg[+]) status influences DLBCL patient survival.
Main Methods:
- Retrospective analysis of 602 DLBCL cases from January 2011 to December 2021.
- Inclusion of general clinical data and survival time analysis.
- Application of univariate and multivariate Cox regression analyses.
Main Results:
- HBsAg[+] patients (25.6%) presented with more advanced disease, higher IPI scores, B symptoms, impaired liver function, and higher recurrence rates.
- Median overall survival was 16.5 months for HBsAg[+] vs. 35 months for HBsAg[-] patients.
- HBsAg[+] status was an independent predictor of worse DLBCL prognosis (HR=1.46, p=0.017).
Conclusions:
- Hepatitis B surface antigen positivity is an independent risk factor for poorer DLBCL prognosis.
- Clinical monitoring and management strategies should consider HBsAg status in DLBCL patients.
- Further research focusing on HBsAg[+] DLBCL patients is warranted.
Objectives:
To investigate the basic characteristics of patients with diffuse large B-cell lymphoma (DLBCL) and whether hepatitis B surface antigen positive (HBsAg [+]) affects the survival of patients with DLBCL.
Methods:
The study was carried out at Affiliated Hospital of Hebei University, Baoding, China, including 602 DLBCL cases from January 2011 to December 2021. We analyzed patients' general clinical data and applied multivariate and univariate Cox analyses to assess the factors influencing their survival times.
Results:
The HBsAg(+) and HBsAg(-) groups comprised 154 (25.6%) and 448 (74.4%) of the 602 cases, respectively. HBsAg(+) cases tended to be later-stage (III-IV) with higher international prognostic index (IPI) points (3-5) and a greater tendency toward B symptoms, impaired liver function, and recurrence than HBsAg(-) cases (all p<0.05). After follow-up, 194 (32.2%) patients died. The median overall survival (OS) and 5-year OS rates in the HBsAg(+) and HBsAg(-) groups were 16.5 months (42%) and 35 months (63%), respectively. Cox analyses indicated that HBsAg(+) affected the prognosis of DLBCL cases (HR=1.46, 95%CI=1.07-1.99, p=0.017).
Conclusion:
The HBsAg(+) seems to be an independent hazard factor for the worse prognosis of DLBCL patients; hence, a focus on these patients in clinic is required.
